Mild Leaks: TAVR’s Silent Enemies

Courtesy of Dr. Carlos Fava.

Even though the presence of paravalvular regurgitation (PVR) has been reduced, thank to greater experience and new devices, it is still frequent and has an impact in survival (especially moderate and severe PVR).

Mild Leaks: TAVR’s Silent Enemies

Recent research has shown that mild PVR also has a negative impact. However, these data were provided by a handful of studies and a small meta-analysis.


Read also: Who Lives Longer After TAVR, Men or Women?”.


This meta-analysis included 25 studies with 21018 patients.

 

Globally, the presence of mild PVR (compared to none/trivial PVR) was associated to higher mortality (HR 1.26, 95% CI 1.11-1.43 p=<0.0001) between 6 months and 5 years. Cardiovascular mortality also was higher with mild PVR (HR 1.28, 95% CI 1.05-1.57p=0.002) between 1 and 3 years.

 

When analyzed by subgroups, PVR was also associated to high mortality.


Read also: Transcatheter Mitral Valve Replacement Devices Multiply”.


In the non-surgical or high surgical risk group, there was higher mortality (18 studies 17,002 patients HR 1.27, 95% CI 1.09-1.47 p=0.002), but that was not the case in the low or intermediate risk group (HR 1.27 95% CI 0.95-1.69 p=0.11).

 

As regards devices, balloon-expandable valves were associated with increased mortality (HR 1.41, 95% CI 1.05-1.89, p=0.002), which was not the case with self-expandable valves (HR 1.21 0.79-0.81 p=0.38).

 

Conclusion

The presence of PVR was associated with increased all-cause mortality and cardiovascular death after TAVR. TAVR in patients with mild PVR might result beneficial, but this is yet to be determined.

 

Comment

At present, this is the largest meta-analyzis to show the presence of PVR is associated with increased mortality: 26% increase in all-cause mortality (6 months to 5 years) and 28% increase in cardiovascular mortality (between 1 and 3 years).

 

This was not the case of intermediate or low risk patients and this might be because they do not present as many comorbidities, they are not as frail, and they have more myocardial reserve to tolerate volume burden.

 

These data should make us especially demanding when choosing devices. However, PVR will eventually decrease, since we will have better technology and more experience.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Does mild paravalvular regurgitation post-transcatheter aortic valve implantation affect survival? A meta-analyzis.

Reference: Tomo Ando, et al. Catheter Cardiovasc Interv 2018;91:135-147


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...